Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The availability of all GLP-1 agonist medicationsin particular semaglutide and tirzepatidehave been a legitimate concern for patients
A person with a BMI of 24 in India can carry the same metabolic risk as someone with a BMI of 30 in Europe.[11] The WHO has recommended lower BMI cut-offs for overweight (23 kg/m) and obesity (25 kg/m) in Asian populations for precisely this reason.[16] The 2026 Turning Point: Affordable Access For years, GLP-1 medications were priced out of reach for most Indians
Key takeaways Victoza (liraglutide) is an injectable GLP-1 agonist, while Jardiance (empagliflozin) is an oral SGLT2 inhibitor
Semaglutide has become a primary prescription medication for weight management, with clinical trials demonstrating an average weight loss of 15% over 68 weeks in patients with obesity
US$ 29.81
US$ 23.94
US$ 27.70
US$ 25.82
US$ 29.95
US$ 22.50
